NEWS
Waist Tests Split BMI Obesity From a Lower Death Risk
A four-country study finds BMI-only obesity had no extra death risk, while clinical obesity with organ damage raised deaths 69%.
Body mass index both overcounted and missed obesity in 844,108 adults from China, the United Kingdom, the United States and Spain. A combined waist-and-BMI definition raised obesity rates only 3.3 to 7.4 points. People BMI called overweight or obese without a high waist died at lower rates than people of usual weight.
The analysis of 844,108 adults, published November 11 and led by An Pan of Huazhong University of Science and Technology with Francesco Rubino of King’s College London, tested the Lancet Commission’s two-step diagnosis. Excess fat had to be confirmed at the waist. Illness then required organ damage tied to that fat, a state the commission named clinical obesity.
BMI Both Overcounted and Missed Excess Fat
The four cohorts were the Kailuan Study in China (137,795 adults), UK Biobank (436,203), the U.S. All of Us Research Program (218,841) and SIDIAP primary-care records in Catalonia (51,269). Adults were 18 to 74 and free of stroke, heart attack and cancer at the start.
BMI obesity used 30 kg/m² in Western groups and 28 in Chinese adults. The combined definition, which the authors call CAD-obesity, also counted a high waist circumference or waist-to-height ratio when BMI was already in the obese band, and both waist marks when BMI sat in the overweight band. BMI of 40 or higher counted as excess fat with no extra tape.
OBESITY SHARE BY DEFINITION AND COHORT
| Cohort | BMI obesity | Combined (CAD) obesity | Point change |
|---|---|---|---|
| Kailuan, China | 17.8% | 21.3% | +3.5 |
| UK Biobank | 24.0% | 27.3% | +3.3 |
| All of Us, USA | 42.5% | 48.1% | +5.6 |
| SIDIAP, Spain | 18.7% | 26.1% | +7.4 |
BMI labelled obesity without a high waist in 3.1% of the Chinese cohort, 1.9% in Britain, 1.9% in the U.S. group and 1.2% in Spain. The larger miss ran the other way. Among people BMI called merely overweight, 6.6%, 5.2%, 7.5% and 8.6% already met both waist marks for obesity-level fat.
Rubino, chair of metabolic and bariatric surgery at King’s College London, said that in large countries those shares mean tens of millions of people assigned to the wrong bin. “Those people effectively are overdiagnosed with a disease,” he said of the BMI-obese group with no high waist, speaking at a briefing on the paper. He also said many people still parked in overweight “may even have clinical obesity disease as a result.”
A 0.50 Waist Line Sent U.S. Counts Soaring
That modest rise clashes with U.S. analyses that used a single waist-to-height line of 0.50 and, in some cases, applied waist rules to people with a normal BMI. Lindsay Fourman and colleagues, working in the All of Us program, put obesity at 68.6% in 301,026 adults, versus 42.9% by BMI. This paper’s U.S. sample, 218,841 people, landed at 48.1% versus 42.5%.
The gap is the cut-off, and who gets measured. The authors limited waist checks to the usual overweight and obese BMI bands, following the commission’s screen-then-confirm design. They also used higher, ethnicity-specific waist-to-height lines, not 0.50. A 0.50 line, they found, sits near the BMI overweight threshold. Obesity-level fat and rising death clustered around 0.55 and above.
WAIST-TO-HEIGHT 0.50 VERSUS ETHNICITY-SPECIFIC LINES
| Cohort | Share above 0.50 | Share above ethnicity-specific line |
|---|---|---|
| Kailuan, China | 59.2% | 18.3% |
| UK Biobank | 66.7% | 27.2% |
| All of Us, USA | 74.3% | 48.8% |
| SIDIAP, Spain | 71.1% | 33.3% |
People whose ratio sat between 0.50 and the ethnicity-specific line had a pooled death hazard ratio of 0.99, with a 95% confidence interval of 0.97 to 1.02, which is no extra risk. Above the ethnicity-specific line the pooled hazard ratio was 1.21 (1.18 to 1.24). Swap 0.50 into the combined definition and the extra people it flags still show a hazard ratio of 1.00 (0.96 to 1.03). The commission’s own public materials had used 0.50 for white adults. This dataset treats that figure as an overweight mark, not an obesity mark.
Who Carries the Extra Death Risk After Reclassification?
Death records ran a median 15.3 years in Kailuan (17,642 deaths), 13.8 years in UK Biobank (31,812 deaths) and 11.2 years in SIDIAP (2,338 deaths). All of Us was left out of this part because follow-up was short. Models adjusted for age, sex, social measures and smoking, among other cohort-specific factors.
Compared with people who were not overweight or obese, BMI overweight without CAD-obesity had a pooled hazard ratio of 0.88 (0.86 to 0.90). BMI obesity without CAD-obesity sat at 0.93 (0.86 to 0.99). Both are lower death rates. Overweight BMI with CAD-obesity rose to 1.06 (1.03 to 1.10), and BMI obesity with CAD-obesity to 1.07 (1.05 to 1.10). The tape, not the BMI label, marked the extra deaths.
DEATH RISK BY BMI AND WAIST-CONFIRMED OBESITY
| Group | Pooled hazard ratio | 95% CI |
|---|---|---|
| No overweight or obesity | 1.00 (reference) | – |
| BMI overweight, no CAD-obesity | 0.88 | 0.86 to 0.90 |
| BMI obesity, no CAD-obesity | 0.93 | 0.86 to 0.99 |
| BMI overweight with CAD-obesity | 1.06 | 1.03 to 1.10 |
| BMI obesity with CAD-obesity | 1.07 | 1.05 to 1.10 |
| Preclinical obesity (CAD, no organ damage) | 1.19 | 1.14 to 1.24 |
| Clinical obesity (CAD plus organ damage) | 1.69 | 1.64 to 1.73 |
A hazard ratio of 1.69 is a 69% higher death risk; 1.19 is 19% higher. Dropping deaths in the first five years did not change the pattern, which argues against sick people simply weighing less at the start. In UK Biobank, the only cohort with causes of death, CAD-obesity also tracked higher cardiovascular and obesity-related cancer deaths. BMI overweight or obesity without CAD-obesity did not.
The paper puts about 1.5 billion adults in the BMI overweight class, citing the World Obesity Atlas. WHO figures for 2024 count 1.1 billion people living with obesity and 2.6 billion adults as overweight, 940 million of them with obesity. If the lower-risk BMI overweight group is as common as these cohorts suggest, a large share of that overweight class is not a death-risk group at all.
Most Preclinical Cases Did Not Progress in 10 Years
Clinical obesity meant CAD-obesity plus at least one of 18 adult signs in the 2025 diagnostic criteria for clinical obesity, from heart failure and sleep apnea to knee osteoarthritis and limits on daily tasks. Not every coexisting illness is caused by fat, so the authors scaled counts by an attributable fraction from each cohort’s hazard ratio linking CAD-obesity to new organ damage (1.62 in Kailuan, 1.68 in UK Biobank, 1.67 in All of Us, 2.07 in SIDIAP).
After that adjustment, clinical obesity was 26.3% of obesity in China, 30.5% in Britain, 22.7% in the U.S. sample and 31.3% in Spain. In the full adult samples it was 5.6%, 8.3%, 10.9% and 8.2%. Crude organ damage among people with CAD-obesity still ran from 56.7% in All of Us to 75.3% in UK Biobank. The green slice, people with confirmed extra fat and no detected organ damage, is the floor for preclinical obesity.
HOW THE DEFINITION LANDED
- January 14, 2025: The Lancet Diabetes & Endocrinology Commission, chaired by Rubino, publishes the two-category diagnosis and asks clinicians to confirm extra fat at the waist rather than trust BMI alone.
- October 15, 2025: Fourman and colleagues, applying a 0.50 waist-to-height line and waist rules even at normal BMI in All of Us, report obesity at 68.6% versus 42.9% by BMI.
- November 11, 2026: Pan, Rubino and colleagues publish the four-country test with ethnicity-specific waist lines, attributable-fraction clinical counts, 10-year progression and death follow-up.
Among people who started with CAD-obesity and no organ damage, the attributable-fraction 10-year incidence of clinical obesity was 21.2% in Kailuan, 8.7% in UK Biobank and 22.6% in SIDIAP. All of Us, with shorter follow-up, had an 8.5% four-year figure. Kailuan’s higher rate may reflect biennial clinic exams rather than a different biology. Sensitivity checks that used only the nine organ signs available in every dataset barely moved the numbers.
10-YEAR MOVE FROM PRECLINICAL TO CLINICAL
- Kailuan: 21.2% incidence among 8,009 people with preclinical obesity at baseline.
- UK Biobank: 8.7% among 29,338 people.
- SIDIAP: 22.6% among 5,273 people.
- All of Us: 8.5% at four years among 54,535 people, not a 10-year figure.
Prescription rules for GLP-1 weight-loss drugs are still written in BMI. A definition that finds no extra deaths in BMI obesity without a high waist, and a 69% extra death risk only after organ damage, puts those labels and this prognosis on different maps.
Endocrine Society Still Objects to the Extra Steps
Amy Rothberg, an endocrinologist at the University of Michigan and lead author of the Endocrine Society’s reply to the 2025 commission, said the new numbers do not answer her earlier objections. Proving that organ damage is caused by extra fat is hard in clinic and can delay treatment, she said, and the extra steps could widen gaps in who gets care.
The rates of misclassification based on BMI are relatively small, and the added complexity hardly seems to warrant changing the definition to include the additional measures. In addition, the risk of all-cause mortality among people with ‘pre-obesity’ is still 19% higher (as opposed to 69%), but 19% is not negligible.
Amy Rothberg, endocrinologist, University of Michigan
Pan, speaking at the same briefing as Rubino, said many clinicians are already asking whether 18 organ signs are too many. “We’re now trying to further refine our criteria and see if we can come up with different versions that can be adapted to clinics which have different resources and capacities,” he said. Rubino argued that a history and physical exam pick up most of the damage, the same work other diseases already demand.
Body mass index alone cannot tell us whether someone is already ill or at risk of illness, or what care they need, leaving people vulnerable to both undertreatment and overtreatment. The new definition makes personalised, proportionate care possible whereas a uniform BMI-based definition prevents it.
Francesco Rubino, chair of metabolic and bariatric surgery, King’s College London
The European Association for the Study of Obesity and the Obesity Medicine Association warned in 2025 that a “preclinical” label could slide into watchful waiting. The authors answer that the split is a snapshot of current health, like prediabetes versus diabetes, and does not by itself bar lifestyle treatment, drugs or, in selected cases, surgery. Rothberg’s 19% extra death risk in the preclinical group is the live tension in that reply: it is smaller than 69%, and it is not zero.
Sonia Anand, an epidemiologist at McMaster University, said the ethnicity-specific lines still need testing against new diabetes, heart disease and organ outcomes in South Asian, Indigenous and other underrepresented groups. Kailuan covers Chinese workers; the other three cohorts are Britain, a diverse U.S. sample and Catalonia. That is not a global map.
What Waist-to-Height Ratio Counts as Obesity-Level Fat?
Waist circumference used 102 cm in men and 88 cm in women in Western groups, and 90 cm and 85 cm in Chinese adults. Waist-to-height lines came from Leila Itani and Marwan El Ghoch’s ethnicity-specific waist-to-height cut-offs in NHANES 2011 to 2018, set against visceral fat on DXA scans in people with overweight.
ETHNICITY-SPECIFIC WAIST-TO-HEIGHT CUT-OFFS
- Non-Hispanic white: 0.57 in men, 0.58 in women.
- Non-Hispanic Black: 0.55 in men, 0.57 in women.
- Hispanic: 0.57 in men, 0.59 in women.
- Asian: 0.56 in men, 0.59 in women.
- Others: 0.50.
BMI and waist-to-height ratio tracked together, with Pearson r of 0.64 or higher in every cohort. Fitted lines put a 0.50 ratio near overweight BMI, and the BMI obesity line near 0.55 to 0.60. Restricted cubic splines showed death risk turning up around 0.55. A clinic tape is cheap. The argument is which mark on that tape is the disease line, and whether BMI obesity without that mark should still open the same treatment door.
Records used billing codes rather than a standard physical exam, and not every cohort held all 18 signs, so some damage was likely missed. The attributable fraction cannot assign cause in one patient. No company funded the work. Rubino has reported research grants from Ethicon, Novo Nordisk and Medtronic and speaking fees from several drug and device makers, which he disclosed with the paper.
Frequently Asked Questions
What Is Clinical Obesity Versus Preclinical Obesity?
Clinical obesity is confirmed extra body fat plus at least one obesity-related organ problem or a clear limit on daily tasks. Preclinical obesity is the same extra fat with organs and whole-body function still intact. The 2025 commission treats the first as a chronic illness and the second as a risk state. In this study the metabolic sign counted only when high blood sugar occurred together with low HDL cholesterol and high triglycerides, not when diabetes or abnormal lipids appeared alone.
What BMI and Waist Cut-Offs Did the Study Use for Chinese Adults?
Chinese participants met the obese BMI band at 28 kg/m² and the overweight band at 24, versus 30 and 25 in the Western cohorts. Waist circumference used 90 cm in Chinese men and 85 cm in Chinese women, versus 102 cm and 88 cm in Western groups. BMI of 40 or higher counted as excess fat in every cohort without a waist check.
Why Did Some U.S. Analyses Put Obesity Near 70 Percent?
Those analyses used a single waist-to-height cut-off of 0.50 and, in Fourman’s All of Us paper, also labelled “anthropometric-only” obesity in people whose BMI was still in the normal range. This study kept waist confirmation inside the overweight and obese BMI bands and used higher ethnicity-specific ratios. In the same U.S. program it found 48.1% combined obesity, not 68.6%.
How Often Did Preclinical Obesity Become Clinical Obesity?
The attributable-fraction 10-year incidence was 8.7% in UK Biobank, 21.2% in Kailuan and 22.6% in SIDIAP. All of Us had only a four-year figure, 8.5%. Restricting the analysis to the nine organ signs shared across datasets gave 8.8% in UK Biobank and 21.4% in Kailuan, almost the same as the main result.
Why Was the U.S. Cohort Left Out of the Death Analysis?
All of Us follow-up was too short for the all-cause death models used in Kailuan, UK Biobank and SIDIAP. It still contributed prevalence, the clinical versus preclinical split, and the four-year progression estimate. Cause-specific death was available only in UK Biobank.
Disclaimer: This article is news reporting on a published research paper and is for information only. It is not medical advice, a diagnosis, or a recommendation to start, stop, or change any obesity treatment, including medicines or surgery. Readers should discuss BMI, waist measures, and any treatment decision with a qualified physician or registered dietitian who knows their history. Figures, cohort counts, and diagnostic cut-offs reflect the paper and the sources cited with it and may change if later studies or guidelines use different thresholds.
-
NEWS3 months agoMeta’s Smart Glasses Sell a Light That Needed Two Patches
-
NEWS3 months agoApple’s New Mac Studio Clusters Local AI on the Desk
-
NEWS3 months agoGoogle’s Free AI Pro Year Is Three Different Deals
-
NEWS3 months agoSong Yadong Stops Umar Nurmagomedov the Only Way Left
-
ENTERTAINMENT3 months agoLanterns Puts Sinestro in a Cell and Lets Him Talk
-
NEWS3 months agoThe Mahape Fake Apple Raid Repeats a Dual-Shift Pattern
-
ENTERTAINMENT3 months agoLUN8’s First London Concert Filled a 620-Cap Club
-
NEWS3 months agoOpenAI Agents Hit Hugging Face to Cheat a Test
